Not specifiedRegulatory Approvalregulatorymid-term

Alembic Pharmaceuticals submits ANDA220499 for FDA review

Importance6/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Alembic Pharmaceuticals14 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/16/2026, 12:33:03 AM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of ANDA220499 by Alembic Pharmaceuticals signals their intent to enter a competitive market, which could disrupt existing players. Portfolio teams must evaluate the implications of this entry on market dynamics and potential shifts in competitive positioning. Regulatory context from FDA (FDA TA — ANDA220499) supports the near-term read. Assessment grounded in 14 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market entry and competitive dynamics resulting from this submission. The strongest clinical anchor is A Study to Learn About Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease (ClinicalTrials.gov), sponsor/company relevance (pfizer). In Not specified, 5 regulatory and 2 competitive items passed relevance filtering for Alembic Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals. The submission of ANDA220499 indicates Alembic's intention to enter a competitive market, potentially impacting existing players.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — ANDA220499 (FDA). Entity match (alembic pharmaceuticals); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The standard review priority indicates a typical timeline for FDA evaluation, which could lead to approval and market entry if successful.

Key Risks

Elevated medium regulatory exposure for Alembic Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Alembic's entry could affect market share and pricing strategies of existing competitors, potentially impacting revenue streams.
Portfolio teams should assess the potential market entry and competitive dynamics resulting from this submission.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review progress and any subsequent approval announcements related to ANDA220499.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — ANDA220499
FDAhigh relevance
Entity match (alembic pharmaceuticals); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — ANDA219207
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OSELTAMIVIR PHOSPHATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DAPSONE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
MHRA safety review gives UK plasma donations go ahead
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

A Study to Learn About Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Characterization of Phenotypic and Genotypic Regressors for Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Nociception Phenotype in Individuals With Intellectual Disability
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanomaterial-based vaccines: An advanced approach against rotavirus: A review article.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Alembic Pharmaceuticals
ANDA220499

Commercial impact

medium

Alembic's entry could affect market share and pricing strategies of existing competitors, potentially impacting revenue streams.

Regulatory impact

medium

The standard review priority indicates a typical timeline for FDA evaluation, which could lead to approval and market entry if successful.

What to watch

Monitor the FDA's review progress and any subsequent approval announcements related to ANDA220499.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.